BMJ Open

Relationship between serum lipid level and colorectal cancer: a systemic review and meta-analysis

Zhenpeng Yang,[1] Huazhen Tang,[1] Shuai Lu,[1] Xibo Sun,[1,2] Benqiang Rao [1]

[1]General Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China
[2]Breast Surgery, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China

Correspondence to
Dr Benqiang Rao;
raobenqiang@bjsjth.cn

ABSTRACT

Objective Investigative studies report contradictory results of the relationship between serum lipid levels and the risk of colorectal cancer (CRC). We conducted a meta-analysis of prospective published studies to clarify the relationship between serum lipid and CRC risk.
Design Systematic review and meta-analysis.
Data Sources PubMed and Embase from inception until December 2020.
Eligibility criteria We considered prospective cohort and case–control studies that evaluated differences in serum lipid levels with the risk of developing CRC.
Data extraction and synthesis Two independent reviewers screened and included the studies using standardised electronic data extraction forms. The relative risks of the studies were combined with random-effect and fixed-effect models and were analysed for heterogeneity, publication bias and sensitivity.
Results Twenty-four prospective studies, including 4 224 317 individuals with 29 499 CRC cases, were included in the meta-analysis. The total pooled risk ratio (RR) for high vs low concentrations of triglyceride (TG) concentrations was reported at 1.21 (95% CI 1.09 to 1.34; I^2=46.8%), total cholesterol (TC) was at 1.15 (95% CI 1.08 to 1.22; I^2=36.8%), high-density lipoprotein cholesterol (HDL-C) was 0.86 (95% CI 0.77 to 0.97; I^2=28.8%) and low-density lipoprotein cholesterol (LDL-C) was observed at 1.03 (95% CI 0.75 to 1.41; I^2=69.4%).
Conclusions This meta-analysis shows that high levels of serum TG and TC are positively correlated with the incidence rate of CRC, while high levels of serum HDL-C are negatively correlated with CRC incidence rate. Furthermore, no association was found between LDL-C and the risk of developing CRC. Nevertheless, the heterogeneity brought about by comparative methods, demographic differences and pathological differences between the research subjects limits the effectiveness of the overall pooled results.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ The main strengths of this research are its comprehensive, prospective design, large sample size and long follow-up time.
⇒ The final result of this study is supported by high-quality studies and a thorough sensitivity analysis.
⇒ The significant heterogeneity still exists in the study results, which may limit the effectiveness of the overall pooled results.
⇒ Comparing the highest reading of the serum lipid group with the lowest group would produce different estimates, creating heterogeneity.
⇒ Demographic differences and pathological differences in cancer may have caused significant heterogeneity.

the relationship between the lipid profile and the risk of CRC is key to understanding the occurrence of CRC. As lipid profiling is convenient, the approach carries an advantage in studying its relationship to CRC.

Blood lipids are the general term used for neutral fats (triglycerides, TG) and lipids (phospholipids, glycolipids and sterols) in plasma.[3] The lipid profile includes TG, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).[4 5] Past studies have shown that serum lipids were closely related to cardiovascular diseases.[6] In recent years, evidence shows that plasma lipid levels may be closely related to the occurrence and development of cancer[7] and thus can be used to evaluate cancer prognosis.[8] However, the relationship between lipid profile and CRC has been inconsistent.[9 10] For example, some studies[11–15] have found an increased risk of CRC in subjects with high serum TG, while others[16–23] report contrary or insignificant associations. Similar trends were found for subjects with high TC, where an increased risk of CRC was observed,[15 18 24–27] while other studies found contrary or insignificant associations.

INTRODUCTION

Colorectal cancer (CRC) has a high incidence rate, a high mortality rate, rapid progress and uncomplicated metastasis, which poses a significant threat to public health.[1] Evidence shows that lipid imbalance is one of the main risk factors for CRC through associations with inflammation, oxidative stress and insulin resistance.[2] Therefore, exploring

In addition, studies on the association between HDL-C and the risk of CRC are also contradictory.[11 12 14 16–20 23 28 29] The relationship between LDL-C and the risks associated with CRC has not been confirmed due to few studies.[11 18 19 23 29] Two meta-analyses of lipid composition and risk of CRC were published in 2014 and 2015. One of the studies showed that elevated serum TG and TC levels are associated with an increased risk of CRC.[30] While others showed that high levels of serum TG, TC and LDL-C were positively associated with colorectal adenoma but not with CRC.[31] The possible reason for the difference is that the latter included prospective studies while the other included retrospective studies.

In the current meta-analysis, more recent studies were included to further evaluate the unclear relationship between serum lipid levels and CRC. A systematic review was conducted with a meta-analysis of all prospective studies related to lipid components to explore the relationship between serum lipid and CRC risk.

MATERIALS AND METHODS
Search strategy
Systematic review and meta-analysis were performed according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.[32] Two independent reviewers searched PubMed and Embase databases for all literature from inception to December 2020. The keywords included 'serum lipids', 'triglycerides, TG', 'total cholesterol, TC', 'high-density lipoprotein cholesterol, HDL-C, or 'low-density lipoprotein cholesterol, LDL-C' combined

with 'colorectal cancer, CRC'. The detailed search strategy is shown in online supplemental table S1.

All references in the selected articles were manually reviewed to ensure that more published studies were found. The two researchers also screened the reference list for review articles and further searched the articles for other eligible studies. The search results were limited to studies published in English.

Study selection
Studies that met the following criteria were included in the meta-analysis: (1) prospective research; (2) study subjects were adults (older than 18 years); (3) serum TG, TC, HDL-C, or LDL-C concentrations were parameters of interest; (4) colorectal, colon or rectal cancer incidence were the outcome of interest and (5) reported the risk ratio (RR) or the HR with estimates of their corresponding 95% CI. Two reviewers (ZY and HT) independently evaluated potentially eligible studies using the above inclusion criteria. Twenty-four potential prospective studies from 5143 articles were identified (figure 1). If there were multiple articles in the same study population, articles with a larger sample size were selected.

Data extraction
The following information was extracted from each study: first author's name, publication year, geographic location, study design, sample size, study participants' age range, follow-up years, colonoscopy examination at the time of diagnosis, study specific-adjusted estimates with their 95% CIs for the highest versus lowest concentrations, and factors matched by or adjusted for the design or data


Figure 1 Flow diagram of the literature search and trials selection process. CRC, colorectal cancer.

analysis. Data from each eligible study were extracted by two independent reviewers (ZY and HT), with disagreements resolved with a majority vote by all coresearchers. When a study provides multiple risk estimates, risk estimates that reflect the maximum control degree of potential confounding factors were extracted.

Quality assessment

The Newcastle-Ottawa Scale (NOS) was used to separately assess the quality of each study by both reviewers. The scores of eight or more, five to seven, and lower than five were considered high-quality, medium-quality and low-quality research, respectively.

Statistical analysis

Statistical analyses were performed using the Stata software (V.14.2). The risk estimates were extracted from each study, and the summary RRs and 95% CIs for the highest vs lowest concentrations of the selected parameters were calculated according to different heterogeneity. For undetected heterogeneity, the fixed-effect or random-effect models were used when significant heterogeneity was detected. In studies that did not use the lowest concentration class as a reference, RR was calculated according to the method provided by Hamling *et al*.[30 33] Additionally, I^2 statistics were used to represent the heterogeneity of studies. I^2 values of <30%, 30%–50% and >50% represent no heterogeneity, moderate heterogeneity and high heterogeneity, respectively. The heterogeneity between subgroups was evaluated by meta-regression, and p<0.05 indicated statistically significant results. Publication bias was analysed using Egger's or Begg's test, and p<0.05 indicated significant publication bias. Sensitivity analysis was used to analyse the stability and heterogeneity of the research results.

Patient and public involvement

This is a meta-analysis based on the evidence in the academic literature, and there is no direct participation of patients or the public in the design, implementation and reporting of this research.

RESULTS
Study characteristics

A total of 5143 studies were obtained after the search using the above keywords. Of these, 1250 publications were excluded due to duplication. The remaining 3893 studies were further evaluated according to their abstracts and titles, and 135 were screened out. Through intensive reading of the full text, studies not associated with serum lipids and the risk of CRC and having repeated research data were excluded. In addition, five studies were manually added after reading the relevant literature. Finally, 24 prospective studies that met the inclusion criteria, published between 1986 and 2019, and involved 4 224 317 individuals with 29,499 CRC events were included. Eight studies were conducted in North America,[11 20–23 34–36] 11 in Europe[12 13 15 17–19 24 27–29 37] and 5 in Asia.[14 16 25 26 38] The median duration of follow-up was 12.9 years. Characteristics of these studies are summarised in online supplemental table S2.

Quality assessment

NOS scores of the 24 prospective studies are shown in online supplemental table S3. Most studies scored 8 or 9, representing 79.2% (19 of 24) of all studies, while the lowest score was 5. Inadequate adjustment of potential confounding factors is the most common problem in low-quality studies, followed by the integrity and duration of follow-up.

Serum TG

Thirteen studies reported serum TG (nine cohort studies, two nested case–control studies and two case–cohort studies). These reports were published between 1997 and 2019 and involved 11 023 CRC cases (online supplemental table S2). Five studies were conducted in North America, six in Europe and two in Asia. The results of 13 studies showed that serum TG had a significant association with the risk of CRC (RR 1.21; 95% CI 1.09 to 1.34), with evidence of moderate heterogeneity (p=0.007, I^2= 46.8%; table 1; figure 2). The Egger's (p=0.834) and Begg's test (p=0.413) showed no evidence of publication bias, and no asymmetry was observed in funnel plots with visual inspection.

Serum TC

Fifteen studies reported serum TC (11 cohort studies, 2 nested case–control studies and 2 case-cohort studies) published between 1986 and 2017. These studies involved a total of 20 454 CRC cases (online supplemental table S2).[11 15 17–19 24–28 34–38] Four studies were conducted in North America,[11 34–36] eight in Europe[15 17–19 24 27 28 37] and three in Asia.[25 26 38] Results from 16 studies showed that serum TC was significantly associated with risk of CRC (RR 1.15; 95% CI 1.08 to 1.22), with evidence of moderate heterogeneity (p=0.017, I^2=36.8%; online supplemental table S4; figure 3). The Egger's (p=0.611) and Begg's test (p=0.560) showed no evidence of publication bias, and no asymmetry was observed in the funnel plots when visually inspected.

Serum HDL cholesterol

Eleven studies reported serum HDL-C (eight cohort studies, one nested case–control study and two case-cohort studies) published between 1997 and 2019 and involved 5869 CRC cases (online supplemental table S2).[11 12 14 16–20 23 28 29] Three studies were conducted in North America,[11 20 23] six in Europe[12 17–19 28 29] and two in Asia.[14 16] Results from these 11 studies showed that serum HDL-C had a significant association with CRC risk (RR 0.86; 95% CI 0.77 to 0.97), with evidence of little heterogeneity (p=0.117, I^2=28.8%; online supplemental table S5; figure 4). The Egger's (p=0.252) and Begg's tests (p=0.124) showed no evidence of publication bias, and

Table 1 Subgroup analysis of the correlation between serum triglyceride concentrations and colorectal cancer risk

	No of studies	Summary RR (95% CIs)	I^2 value (%)	P_h*	P_h†
Overall					
Colorectal cancer	13	1.21 (1.09 to 1.34)	46.8	0.007	
Colon cancer	4	1.29 (0.98 to 1.70)	68.5	0.007	
Rectal cancer	4	1.02 (0.76 to 1.37)	42.5	0.122	
Subgroup analyses					
Study quality					0.801
Medium	3	1.24 (0.97 to 1.58)	52.1	0.100	
High	10	1.20 (1.07 to 1.34)	45.7	0.016	
No of cases					0.311
<338	7	1.12 (0.89 to 1.41)	54.0	0.017	
≥338	6	1.24 (1.11 to 1.38)	43.4	0.053	
Follow-up years					0.682
<13	7	1.15 (0.97 to 1.37)	55.1	0.007	
≥13	6	1.24 (1.09 to 1.40)	35.4	0.135	
Geographical location					0.303
North America	5	1.13 (0.88 to 1.45)	51.1	0.069	
Europe	6	1.29 (1.15 to 1.45)	37.3	0.093	
Asia	2	0.98 (0.69 to 1.40)	65.3	0.021	
Gender					0.533
Male	5	1.32 (1.04 to 1.66)	63.9	0.007	
Female	5	1.19 (0.97 to 1.47)	41.0	0.118	
Adjustment for confounders					
Body mass index					0.347
Yes	7	1.26 (1.10 to 1.44)	42.1	0.054	
No	6	1.12 (0.94 to 1.34)	56.3	0.015	
Alcohol drinking					0.196
Yes	9	1.14 (1.02 to 1.29)	32.1	0.112	
No	4	1.31 (1.10 to 1.55)	51.2	0.045	
Cigarette smoking					0.801
Yes	10	1.20 (1.07 to 1.34)	45.7	0.016	
No	3	1.24 (0.97 to 1.58)	52.1	0.100	
Physical activity					0.654
Yes	7	1.15 (1.07 to 1.25)	0	0.496	
No	6	1.17 (1.00 to 1.36)	60.6	0.002	
Dietary factors					0.346
Yes	4	1.36 (1.10 to 1.68)	0	0.551	
No	9	1.17 (1.05 to 1.32)	55.0	0.003	
Two aforementioned confounders					0.801
Yes	10	1.20 (1.07 to 1.34)	45.7	0.016	
No	3	1.24 (0.97 to 1.58)	52.1	0.100	
Three aforementioned confounders					0.347
Yes	8	1.15 (1.00 to 1.32)	36.9	0.081	
No	5	1.28 (1.09 to 1.49)	51.0	0.038	

*P value for heterogeneity within each subgroup.
†P value for heterogeneity between subgroups with meta-regression analysis.
RR, relative risk.

Figure 2 Forest plots on the association between serum triglyceride concentrations and colorectal cancer risk. RR, risk ratio.

no asymmetry was observed in the funnel plots when visually inspected.

Serum LDL cholesterol

Five studies reported serum LDL-C (three cohort studies, one nested case–control study and one case-cohort study). These reports were published between 1997 and 2016 and involved a total of 2,162 CRC cases (online supplemental table S2).[11 18 19 23 29] Two studies were conducted in North America[11 23] and three in Europe.[18 19 29] The association of serum LDL-C with CRC risk was not observed (RR


Figure 3 Forest plots on the association between serum total cholesterol concentrations and colorectal cancer risk. RR, risk ratio.


Figure 4 Forest plots on the association between high-density lipoprotein cholesterol concentrations and colorectal cancer risk. RR, risk ratio.

1.03; 95% CI 0.75 to 1.41). A random-effects model was constructed due to statistically high heterogeneity among the studies (p=0.001, I^2=69.4%; online supplemental table S6; online supplemental figure 1). The Egger's (p=0.343) and Begg's test (p=0.474) showed no evidence of publication bias, and no asymmetry was observed in the funnel plots when visually inspected.

Subgroup analysis

To explore the source of heterogeneity, several preplanned subgroup analyses were conducted on the studies' characteristics. For study quality, a significant correlation was observed between TG and CRC risks in high-quality studies (RR 1.20; 95% CI 1.07 to 1.34). A similar correlation was found in high-quality studies with TC (RR 1.14; 95% CI: 1.06 to 1.21) and HDL-C (RR 0.87; 95% CI 0.77 to 0.98). A significant correlation was also observed between TG and CRC in the subgroups within the studies with the number of cases ≥338 (RR 1.24; 95% CI 1.11 to 1.38). In subgroups with follow-up at ≥13 years, higher TG levels increased the risk of CRC (RR 1.24; 95% CI 1.09 to 1.40). Furthermore, the RR for the association between TC and CRC risks was similar in Europe (RR 1.20; 95% CI 1.06 to 1.36) and Asia (RR 1.14; 95% CI 1.08 to 1.20). A significant correlation was also found between TG and CRC risks in the European subgroup (RR 1.29; 95% CI 1.15 to 1.45). However, an opposite trend was observed between HDL-C and CRC risks in the North American subgroup (RR 0.75; 95% CI 0.60 to 0.94). Furthermore, TG (RR 1.32; 95% CI 1.04 to 1.66) was associated with a higher risk of CRC in male patients, while TC (RR 1.22; 95% CI 1.11 to 1.34) or LDL-C (RR 1.33; 95% CI 1.01 to 1.76) levels were associated with a higher risk of CRC in female patients.

Sensitivity analyses

Sensitivity analyses were performed to explore the combined effect and heterogeneity among serum lipid levels and CRC studies. After studies related to TG were individually excluded, the combined effect quantity trend remained prior to exclusion. This indicates a good stability of the analysed data. A considerable part of the heterogeneity was determined to be accounted for in one study.[14] Exclusion of the study resulted in moderate heterogeneity (p=0.046, I^2=38.3%), and the RR for CRC was 1.23 (95% CI 1.12 to 1.36).

Additionally, studies that involved TC demonstrated the stability of results. Most of the heterogeneity was accounted for in three studies,[18 19 34] which reported the association between TC and CRC. After excluding these three studies, heterogeneity was nil (p=0.609, I^2=0.0%) and the RR for CRC was 1.16 (95% CI 1.11 to 1.21). As studies related to HDL-C were individually excluded, the trend of combined effect quantity remained as before exclusion, indicating good stability of the analysed results. After excluding study[19] which had the most heterogeneity, heterogeneity dropped to nil (p=0.728, I^2=0.0%) and the RR for CRC was 0.92 (95% CI 0.85 to 0.99).

DISCUSSION

Only prospective studies were included in this meta-analysis, which minimised bias that is usually a concern in retrospective case–control studies. High levels of TG were found to be associated with an increased risk of CRC. High levels of TC were also associated with an increased risk of CRC. These observations help to resolve previous controversies. It is worth noting that the current analysis found that high serum HDL-C concentrations can reduce the risk of CRC, with little evidence of heterogeneity. These results establish the relationship between the lipid profile and the risk of CRC and help predict the occurrence of CRC.

After the exclusion of three studies with high heterogeneity, sensitivity analysis showed no heterogeneity, and that high concentrations of TC increased the risk of CRC. Furthermore, a case–control study showed that higher levels of TC significantly reduced CRC risk. The same study reported that the cancer group, which partially consisted mainly of patients in the advanced stage, had lower TC than the control group.[9] It is hypothesised that the inverse relationship between serum TC and CRC risks results from metabolic or nutritional changes in patients with advanced CRC, rather than increased levels as a protective factor for CRC. In the late stages of CRC, TC concentration decreases due to metabolic changes, competition and rapid consumption of nutrients by cancer cells.[2]

Previous studies have not found a relationship between serum HDL-C levels and CRC risks.[14 20 28] Until 2011, only a nested case–control study showed that high levels of HDL-C reduced the risk of CRC and RR by 0.54 (95% CI 0.39 to 0.77).[19] The current comprehensive analysis of all prospective studies associated with HDL-C and CRC risk identified for the first time their relationship. In addition to obtaining results without heterogeneity, the results' stability was also proved by the sensitivity analysis.

When analysed by anatomical site, the results indicated a positive and significant association between TC and the risk of rectal cancer. On the contrary, there were no significant results for colon cancer, suggesting different causal factors between both anatomical sites.[39] When subgroup analysis stratified by study quality was carried out, TG, TC and HDL-C in high-quality studies were found to be significantly associated with CRC risk. However, in the relationship between TC and CRC risks, the groups with the number of cases of <338 had a more significant association and were not heterogeneous. This may be related to the fact that studies with a small sample size are more likely to show positive results. All studies related to TC ranged from small to large sample size, while the forest map did not show apparent heterogeneity among studies with increased sample size.

Stratified analysis of the subgroups by follow-up years revealed a significant positive association for TG with CRC risks was only observed in the group of ≥13 years. When analysing the risks of TC and CRC, the group with a follow-up time of less than 13 years produced a positive result with less heterogeneity. A further evaluation must be included in the analysis to explain this situation.

When the subgroup analysis was performed by geographical location, a significant positive correlation was observed between TG and CRC risks in Europe. The difference in TG concentration between different research groups was large, while the difference in European studies was relatively small. These differences may be due to regional differences. However, more studies are needed to obtain more reliable evidence, as previous studies are limited in number.

An analysis of gender found that high levels of TG in men are associated with a higher risk of CRC than in women, although the results are highly heterogeneous. High TC levels in female patients are more likely to cause CRC. This may be related to changes in endogenous hormones, but this needs further investigation. In addition, with adjustment of confounding factors, the estimated values of TG and TC for CRC risk decreased while the estimates of HDL-C increased. Adjusting confounding factors also did not reveal a statistically significant correlation between LDL-C at diagnosis and CRC risk.

Some studies have shown that in the process of tumour immunity, immune cells, such as activated T cells, experience rapid proliferation and need to absorb a large amount of cholesterol. Cholesterol is sourced from LDL-C, demonstrating the benefits of LDL-C. Therefore, increasing LDL can help immune cells fight tumour cells.[40] Furthermore, cholesterol helps to establish a mature immune synapse to target and kill cancer cells.[41] Elevated LDL-C levels were observed in patients with cancer cachexia, which may be due to intermediate density lipoprotein (IDL) accumulation, cholesterol

deficiency and LDL-C particle formation. LDL-C has a low affinity for their receptors and persists in the circulation, and this phenomenon is gradually aggravated with the decrease in skeletal muscle. Therefore, the increase in LDL-C can be understood as a secondary phenomenon in patients with cachexia.[42]

Strengths and limitations

The main strengths of the present systematic review and meta-analysis are its comprehensive, prospective design, large sample size and long follow-up time. Many case data ensure the effectiveness of statistical results and a comprehensive evaluation of the relationship between blood lipids and CRC risks. Furthermore, the final result of the current study is supported by high-quality studies and a thorough sensitivity analysis. None of the included studies was rated as having a severe risk of bias, without evidence of publication bias. These factors could further enhance the credibility of the analysis's outcome.

Nevertheless, although a large number of subgroups and sensitivity analyses have not identified these variations as statistically significant sources of heterogeneity, significant heterogeneity still exists in the study results, which may limit the effectiveness of the overall pooled results. This may be because some factors that may affect the incidence are not included, such as life behaviour and eating habits, comorbidities and psychological factors.

Another limitation is that heterogeneity may be introduced, although clear inclusion criteria were used because of differences in comparison methods. Comparing the highest reading of the serum lipid group with the lowest group would produce different estimates, creating heterogeneity. For example, the definitions for high and low categories of blood lipids were different in the initial studies. The studies used different cut-off values, such as classifying blood lipid indexes into two or five categories. A much higher number of studies with high and low lipid levels would help produce higher risk estimates.

Third, demographic differences (male vs female) may have caused significant heterogeneity, which may be caused by differences in incidence rates and changes in endogenous hormone levels. Fourth, there was pronounced heterogeneity due to pathological differences in cancer. Different anatomical parts of the intestinal tract have unique microbial and immune environments. These microbiotas produce inflammatory and carcinogenic metabolites by metabolising lipids. This study cannot consider the impact of microorganisms on localised changes in the intestinal environment. Finally, selected studies were adjusted for major potential confounders. Thus, it cannot be ruled out that the observed correlations were due to unmeasured or residual confounders of other factors. For example, the consumption of statins cannot be adjusted due to the lack of corresponding records.

Implications

Our study suggests that dyslipidaemia may be a risk factor to consider when making clinical decisions on CRC screening and monitoring. These results are significant due to highly inconsistent data reported by numerous studies, which makes it difficult to conclude. The mechanism of hypertriglyceridaemia and the change in cholesterol outflow capacity may benefit future biological research on colon cancer carcinogenesis. More studies are needed to explore the mechanism of lipid metabolism represented by blood lipids in the occurrence of CRC. Evidence of a causal effect would facilitate blood lipid indicators for CRC screening. The ease of measuring lipid levels would further help control lipid metabolism in patients with CRC. In the future, a high-quality, large-scale, multicentre prospective study is needed to confirm the role of blood lipids in the risk of CRC.

CONCLUSION

In summary, this systematic review and meta-analysis demonstrated that high serum levels of TG and TC were positively correlated with the incidence rate of CRC. On the contrary, high serum HDL-C levels were negatively correlated with the incidence rate of CRC. In particular, no association was found between LDL-C and CRC risks. Further clinical studies are needed to verify whether intervention in the concentration of lipid components would reduce CRC incidence.

ORCID iD
Benqiang Rao http://orcid.org/0000-0002-2798-2468

REFERENCES

1. Siegel RL, Miller KD, Fedewa SA, *et al*. Colorectal cancer statistics, 2017. *CA Cancer J Clin* 2017;67:177–93.
2. Stevanovic M, Vekic J, Bogavac-Stanojevic N, *et al*. Significance of LDL and HDL subclasses characterization in the assessment of risk for colorectal cancer development. *Biochem Med* 2018;28:030703.
3. Gazzola K, Reeskamp L, van den Born B-J. Ethnicity, lipids and cardiovascular disease. *Curr Opin Lipidol* 2017;28:225–30.
4. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, *et al*. Triglyceride-Rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TnT trial. *Circulation* 2018;138:770–81.
5. Zhao X, Zhang H-W, Sun D, *et al*. Relation of oxidized-low-density lipoprotein and high-density lipoprotein subfractions in non-treated patients with coronary artery disease. *Prostaglandins Other Lipid Mediat* 2019;144:106345.
6. Charlton F, Tooher J, Rye K-A, *et al*. Cardiovascular risk, lipids and pregnancy: preeclampsia and the risk of later life cardiovascular disease. *Heart Lung Circ* 2014;23:203–12.
7. Dashti SG, Li WY, Buchanan DD, *et al*. Type 2 diabetes mellitus, blood cholesterol, triglyceride and colorectal cancer risk in Lynch syndrome. *Br J Cancer* 2019;121:869–76.
8. Peng F, Hu D, Lin X, *et al*. An in-depth prognostic analysis of baseline blood lipids in predicting postoperative colorectal cancer mortality: the FIESTA study. *Cancer Epidemiol* 2018;52:148–57.
9. Chung YW, Han DS, Park YK, *et al*. Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: a case-control study in Korea. *Dig Liver Dis* 2006;38:668–72.
10. Yamada K, Araki S, Tamura M, *et al*. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. *Int J Epidemiol* 1998;27:794–8.
11. Chandler PD, Song Y, Lin J, *et al*. Lipid biomarkers and long-term risk of cancer in the women's health study. *Am J Clin Nutr* 2016;103:1397–407.
12. Lu Y, Ness-Jensen E, Hveem K, *et al*. Metabolic predispositions and increased risk of colorectal adenocarcinoma by anatomical location: a large population-based cohort study in Norway. *Am J Epidemiol* 2015;182:883–93.
13. Borena W, Stocks T, Jonsson H, *et al*. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. *Cancer Causes Control* 2011;22:291–9.
14. Inoue M, Noda M, Kurahashi N, *et al*. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. *Eur J Cancer Prev* 2009;18:240–7.
15. Tulinius H, Sigfússon N, Sigvaldason H, *et al*. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. *Cancer Epidemiol Biomarkers Prev* 1997;6:863–73.
16. Li X, Chen H, Wang G, *et al*. Metabolic syndrome components and the risk of colorectal cancer: a population-based prospective study in Chinese men. *Front Oncol* 2019;9:1047.
17. Katzke VA, Sookthai D, Johnson T, *et al*. Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort. *BMC Med* 2017;15:218.
18. Agnoli C, Grioni S, Sieri S, *et al*. Colorectal cancer risk and dyslipidemia: a case-cohort study nested in an Italian multicentre cohort. *Cancer Epidemiol* 2014;38:144–51.
19. van Duijnhoven FJB, Bueno-De-Mesquita HB, Calligaro M, *et al*. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European prospective investigation into cancer and nutrition. *Gut* 2011;60:1094–102.
20. Ahmed RL, Schmitz KH, Anderson KE, *et al*. The metabolic syndrome and risk of incident colorectal cancer. *Cancer* 2006;107:28–36.
21. Tsushima M, Nomura AMY, Lee J, *et al*. Prospective study of the association of serum triglyceride and glucose with colorectal cancer. *Dig Dis Sci* 2005;50:499–505.
22. Saydah SH, Platz EA, Rifai N, *et al*. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* 2003;12:412–8.
23. Schoen RE, Tangen CM, Kuller LH, *et al*. Increased blood glucose and insulin, body size, and incident colorectal cancer. *J Natl Cancer Inst* 1999;91:1147–54.
24. Muka T, Kraja B, Ruiter R, *et al*. Dietary polyunsaturated fatty acids intake modifies the positive association between serum total cholesterol and colorectal cancer risk: the Rotterdam study. *J Epidemiol Community Health* 2016;70:881–7.
25. Shin M, Joo J, Yang H-R, *et al*. Risk prediction model for colorectal cancer: National health insurance Corporation study, Korea. *PLoS One* 2014;9:e88079.
26. Kitahara CM, Berrington de González A, Freedman ND, *et al*. Total cholesterol and cancer risk in a large prospective study in Korea. *J Clin Oncol* 2011;29:1592–8.
27. Törnberg SA, Holm LE, Carstensen JM, *et al*. Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. *N Engl J Med* 1986;315:1629–33.
28. Ahn J, Lim U, Weinstein SJ, *et al*. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. *Cancer Epidemiol Biomarkers Prev* 2009;18:2814–21.
29. Gaard M, Tretli S, Urdal P. Blood lipid and lipoprotein levels and the risk of cancer of the colon and rectum. A prospective study of 62,173 Norwegian men and women. *Scand J Gastroenterol* 1997;32:162–8.
30. Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. *Cancer Causes Control* 2015;26:257–68.
31. Tian Y, Wang K, Li J, *et al*. The association between serum lipids and colorectal neoplasm: a systemic review and meta-analysis. *Public Health Nutr* 2015;18:3355–70.
32. Moher D, Liberati A, Tetzlaff J, *et al*. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Open Med* 2009;3:e123–30.
33. Hamling J, Lee P, Weitkunat R, *et al*. Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. *Stat Med* 2008;27:954–70.
34. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of colon and rectal cancer among Hawaii Japanese men. *Ann Epidemiol* 1996;6:276–82.
35. Schatzkin A, Hoover RN, Taylor PR, *et al*. Site-Specific analysis of total serum cholesterol and incident cancer in the National health and nutrition examination survey I epidemiologic follow-up study. *Cancer Res* 1988;48:452–8.
36. Sidney S, Friedman GD, Hiatt RA. Serum cholesterol and large bowel cancer. A case-control study. *Am J Epidemiol* 1986;124:33–8.
37. Strohmaier S, Edlinger M, Manjer J, *et al*. Total serum cholesterol and cancer incidence in the metabolic syndrome and cancer project (Me-Can). *PLoS One* 2013;8:e54242.
38. Iso H, Ikeda A, Inoue M, *et al*. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. *Int J Cancer* 2009;125:2679–86.
39. Cai X, Gu D, Chen M, *et al*. The effect of the primary tumor location on the survival of colorectal cancer patients after radical surgery. *Int J Med Sci* 2018;15:1640–7.
40. Huang B, Song B-L, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. *Nat Metab* 2020;2:132–41.
41. Yang W, Bai Y, Xiong Y, *et al*. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. *Nature* 2016;531:651–5.
42. Pin F, Barreto R, Couch ME, *et al*. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. *J Cachexia Sarcopenia Muscle* 2019;10:140–54.

Supplementary Table S1. Search strategy in the PubMed and Embase

PubMed	Search strategy
#1	"Lipids/blood"[Mesh] OR "Triglycerides"[Mesh] OR "Cholesterol"[Mesh]
#2	"Triacylglycerol"[Title/Abstract] OR "Triacylglycerols"[Title/Abstract] OR "Epicholesterol"[Title/Abstract] OR "alpha Lipoprotein Cholesterol"[Title/Abstract] OR "Cholesterol alpha Lipoprotein"[Title/Abstract] OR "HDL Cholesterol"[Title/Abstract] OR "High Density Lipoprotein Cholesterol"[Title/Abstract] OR "Cholesterol HDL2"[Title/Abstract] OR "HDL2 Cholesterol"[Title/Abstract] OR "Cholesterol HDL3"[Title/Abstract] OR "HDL3 Cholesterol"[Title/Abstract] OR " Low Density Lipoprotein Cholesterol "[Title/Abstract] OR "beta Lipoprotein Cholesterol"[Title/Abstract] OR "Cholesterol beta Lipoprotein"[Title/Abstract] OR "LDL Cholesterol"[Title/Abstract] OR "Cholesteryl Linoleate LDL"[Title/Abstract] OR "LDL Cholesteryl Linoleate"[Title/Abstract] OR "lipids"[Title/Abstract] OR "serum lipid"[Title/Abstract] OR "Triglycerides"[Title/Abstract] OR "Triglyceride"[Title/Abstract] OR "Cholesterol"[Title/Abstract] OR "Total Cholesterol"[Title/Abstract] OR "TG"[Title/Abstract] OR "TC"[Title/Abstract] OR "HDL-C"[Title/Abstract] OR "LDL-C"[Title/Abstract]
#3	#1 OR #2
#4	"Colorectal Neoplasms"[Mesh]
#5	"Colorectal Neoplasms"[Title/Abstract] OR "Colorectal Neoplasm"[Title/Abstract] OR "Neoplasm Colorectal"[Title/Abstract] OR "Colorectal Carcinoma"[Title/Abstract] OR "Carcinoma Colorectal"[Title/Abstract] OR "Carcinomas Colorectal"[Title/Abstract] OR "Colorectal Carcinomas"[Title/Abstract] OR "Colorectal Cancer"[Title/Abstract] OR "Cancer Colorectal"[Title/Abstract] OR "Cancers Colorectal"[Title/Abstract] OR "Colorectal Cancers"[Title/Abstract] OR "Colorectal Tumors"[Title/Abstract] OR "Colorectal Tumor"[Title/Abstract] OR "Tumor Colorectal"[Title/Abstract] OR "Tumors Colorectal"[Title/Abstract] OR "Neoplasms Colorectal"[Title/Abstract] OR "CRC"[Title/Abstract]
#6	#4 OR #5
#7	#3 AND #6

Embase	Search strategy
#1	lipid blood level/exp OR lipids:ab,ti OR serum lipid:ab,ti OR Triacylglycerol/exp OR Triacylglycerol:ab,ti OR Triacylglycerols:ab,ti OR Triglycerides:ab,ti OR Triglyceride:ab,ti OR Cholesterol/exp OR Epicholesterol:ab,ti OR alpha Lipoprotein Cholesterol:ab,ti OR Cholesterol alpha Lipoprotein:ab,ti OR HDL Cholesterol:ab,ti OR High Density Lipoprotein Cholesterol:ab,ti OR Cholesterol HDL2:ab,ti OR HDL2 Cholesterol:ab,ti OR Cholesterol HDL3:ab,ti OR HDL3 Cholesterol:ab,ti OR Low Density Lipoprotein Cholesterol:ab,ti OR beta Lipoprotein Cholesterol:ab,ti OR Cholesterol beta Lipoprotein:ab, ti OR LDL Cholesterol:ab,ti OR Cholesteryl Linoleate LDL:ab,ti OR LDL Cholesteryl Linoleate:ab,ti OR Cholesterol:ab,ti OR Total Cholesterol:ab,ti OR TG:ab,ti OR TC:ab,ti OR HDL -C:ab,ti OR LDL -C:ab,ti
#2	colorectal tumor/exp OR Colorectal Neoplasms:ab,ti OR Colorectal Neoplasm:ab,ti OR Neoplasm Colorectal:ab,ti OR Colorectal Carcinoma:ab,ti OR Carcinoma Colorectal:ab,ti OR Carcinomas Colorectal:ab,ti OR Colorectal Carcinomas:ab,ti OR Colorectal Cancer:ab,ti OR Ca ncer Colorectal:ab,ti OR Cancers Colorectal:ab,ti OR Colorectal Cancers:ab,ti OR Colorectal Tumors:ab,ti OR Colorectal Tumor:ab,ti OR Tumor Colorectal:ab,ti OR Tumors Colorectal:ab,ti OR Neoplasms Colorectal:ab,ti OR CRC:ab,ti
#3	#1 AND #2

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary Table S2. Characteristics of included prospective studies of serum lipids and colorectal cancer risk

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors
Li et al[16]*, 2019, China, CS	394/104,333 (mean, 51.2y), 10y	Men: Triglycerides ≥1.7 vs. <1.7 mmol/l (CRC) HDL cholesterol ≥1.03 vs. <1.03 mmol/l (CRC)	 1.12 (0.90–1.41) 0.81 (0.54–1.19)	Age, education level, income status, frequency of tobacco smoking, frequency of alcohol drinking, and sitting time
Katzke et al[17], 2017, Germany, C-CS	256/25,546 (35-65y), 18y	All: Triglycerides Q4 vs. Q1 (CRC) Total cholesterol Q4 vs. Q1 (CRC) HDL cholesterol Q4 vs. Q1 (CRC)	 1.17 (0.74-1.84) 1.30 (0.84-2.01) 1.12 (0.73-1.73)	Age, sex, baseline height, waist, BMI, lifetime alcohol consumption, red meat intake, fibre intake, smoking status, socioeconomic status, physical activity, diabetes, hypertension and use of lipid lowering drugs
Muka et al[24], 2016, Netherlands, CS	248/6,628 (mean, 69.6y), 22y	All: Total cholesterol 262.55-694.98 vs. 84.94-239.38 mg/dl (CRC)	1.49 (1.08-2.06)	Age, sex, total energy intake, polyunsaturated fatty acids intake, Dutch Healthy Diet index excluding fish and polyunsaturated fatty acids component, processed red meat, unprocessed red meat, dietary fish intake, calcium intake, alcohol intake, physical activity, smoking status, BMI, waist-to-hip ratio, education level, income level, diabetes mellitus, family history of diabetes mellitus, family history of cardiovascular diseases, family history of cancer, history of gallbladder operations, anti-inflammatory and antirheumatic drugs, hormone replacement therapy, lipid lowering mediation drugs

(Continued)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories		RR/HR (95%CI)	Matched/Adjusted potential factors
Chandler et al[11], 2016, USA, CS	198/15,602 (≥45y), 21y	Women:			Age, race, treatment random assignment，hormone replacement therapy, cigarette smoking, exercise, alcohol consumption, postmenopausal status, family history of cancer, aspirin use, history of colon polyps, total vegetable and fruit intake, history of mammogram, red meat intake and BMI
		Triglycerides	Q4 vs. Q1 (CRC)	1.86 (1.17-2.97)	
		Total cholesterol	Q4 vs. Q1 (CRC)	1.21 (0.80-1.84)	
		HDL cholesterol	Q4 vs. Q1 (CRC)	0.63 (0.41-0.98)	
		LDL cholesterol	Q4 vs. Q1 (CRC)	1.14 (0.77-1.68)	
Lu et al[12]*, 2015, Norway, CS	2,044/143,477 (mean, 50.9y), 15y	All:			Age, sex, smoking, alcohol consumption, physical activity, education, family history of cancer, and BMI
		Triglycerides	≥1.7 vs. <1.7 mmol/l (CRC)	1.12 (1.02-1.22)	
		HDL cholesterol	≥1.03 (male) and ≥1.29 (women) vs. <1.03 (male) and <1.29 (women) mmol/l (CRC)	0.93 (0.85-1.03)	
Shin et al [25], 2014, Korea, CS	9,147/1,326,058 (30-80y), 11y	Men:			Age
		Total cholesterol	≥240 vs. ≤200 mg/dl (CRC)	1.16 (1.08-1.26)	
		Total cholesterol	≥240 vs. ≤200 mg/dl (CC)	1.09 (0.97-1.23)	
		Total cholesterol	≥240 vs. ≤200 mg/dl (RC)	1.25 (1.12-1.40)	

(Continued)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories		RR/HR (95%CI)	Matched/Adjusted potential factors
Agnoli et al [18], 2014, Italy, C-CS	286/850 (N/A), 15y	All:			Age, gender, BMI, smoking, total physical activity, alcohol consumption, dietary red meat, dietary fiber, and dietary calcium, and menopause status (for women); stratified by center
		Triglycerides	138.84-1124.07 *vs.* 32.04-89.44 mg/dl (CRC)	1.32 (0.89-1.95)	
		Total cholesterol	246.19-417.46 *vs.* 72.25-204.71 mg/dl (CRC)	1.66 (1.12-2.45)	
		HDL cholesterol	68.54-129.02 *vs.* 24.19-55.10 mg/dl (CRC)	0.85 (0.56-1.28)	
		LDL cholesterol	155.17-290.27 *vs.* 24.10-121.53 mg/dl (CRC)	1.87 (1.27-2.76)	
		Men:			
		Triglycerides	138.84-1124.07 *vs.* 32.04-89.44 mg/dl (CRC)	1.77 (0.88-3.55)	
		Total cholesterol	246.19-417.46 *vs.* 72.25-204.71 mg/dl (CRC)	2.54 (1.35-4.79)	
		HDL cholesterol	68.54-129.02 *vs.* 24.19-55.10 mg/dl (CRC)	0.69 (0.30-1.59)	
		LDL cholesterol	155.17-290.27 *vs.* 24.10-121.53 mg/dl (CRC)	2.90 (1.51-5.56)	
		Women			
		Triglycerides	138.84-1124.07 *vs.* 32.04-89.44 mg/dl (CRC)	1.12 (0.66-1.89)	
		Total cholesterol	246.19-417.46 *vs.* 72.25-204.71 mg/dl (CRC)	1.41 (0.83-2.39)	
		HDL cholesterol	68.54-129.02 *vs.* 24.19-55.10 mg/dl (CRC)	0.87 (0.52-1.47)	
		LDL cholesterol	155.17-290.27 *vs.* 24.10-121.53 mg/dl (CRC)	1.65 (0.97-2.78)	
Strohmaier et al [37], 2013, European, CS	4,935/577,330 (mean, 44y), 11.7y	Men:			Age, BMI, smoking status, and stratified by cohort, fasting status, and birth year
		Total cholesterol	Q5 *vs.* Q1 (CC)	1.18 (0.92-1.51)	
		Total cholesterol	Q5 *vs.* Q1 (RC)	1.09 (0.81-1.48)	
		Women:			
		Total cholesterol	Q5 *vs.* Q1 (CC)	1.23 (0.90-1.69)	
		Total cholesterol	Q5 *vs.* Q1 (RC)	1.48 (0.94-2.32)	

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories		RR/HR (95%CI)	Matched/Adjusted potential factors
Borena et al [13], 2011, European, CS	4,984/514,097 (mean, 44y), 12.7y	Men:			Age, BMI, smoking status, and stratified by cohort, fasting status, and birth year
		Triglycerides	Q5 *vs.* Q1 (CC)	1.96 (1.44-2.67)	
		Triglycerides	Q5 *vs.* Q1 (RC)	1.26 (0.85-1.85)	
		Women:			
		Triglycerides	Q5 *vs.* Q1 (CC)	1.05 (0.75-1.47)	
		Triglycerides	Q5 *vs.* Q1 (RC)	1.33 (0.84-2.13)	
Van Duijnhoven et al [19], 2011, European, NC-CS	1,238/2,476 (mean, 59.0/59.1y), 5.5y	All:			Age, sex, centre, follow-up time, time of blood collection, fasting status, height, weight, smoking
		Triglycerides	≥201.9 *vs.* <79.7 mg/dl (CRC)	1.19 (0.84-1.69)	habits, physical activity, education, consumption of
		Triglycerides	≥201.9 *vs.* <79.7 mg/dl (CC)	1.42 (0.91-2.31)	fruit, vegetables, meat, fish and alcohol, intake of
		Triglycerides	≥201.9 *vs.* <79.7 mg/dl (RC)	1.06 (0.60-1.88)	fibre, energy from fat and energy from non-fat
		Total cholesterol	≥287.7 *vs.* <211.5 mg/dl (CRC)	0.68 (0.50-0.92)	
		Total cholesterol	≥287.7 *vs.* <211.5 mg/dl (CC)	0.66 (0.45-0.98)	
		Total cholesterol	≥287.7 *vs.* <211.5 mg/dl (RC)	0.68 (0.41-1.13)	
		HDL cholesterol	≥70.4 *vs.* <43.3 mg/dl (CRC)	0.54 (0.39-0.77)	
		HDL cholesterol	≥70.4 *vs.* <43.3 mg/dl (CC)	0.42 (0.28-0.65)	
		HDL cholesterol	≥70.4 *vs.* <43.3 mg/dl (RC)	0.79 (0.42-1.49)	
		LDL cholesterol	≥201.5 *vs.* <131.9 mg/dl (CRC)	0.73 (0.54-0.99)	
		LDL cholesterol	≥201.5 *vs.* <131.9 mg/dl (CC)	0.72 (0.48-1.08)	
		LDL cholesterol	≥201.5 *vs.* <131.9 mg/dl (RC)	0.79 (0.48-1.29)	

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories		RR/HR (95%CI)	Matched/Adjusted potential factors
Kitahara et al [26], 2011, Korea, CS	1314/1,189,719 (mean, 44.9y for men/49.3y for women), 12.7y	Men:			Age, cigarette smoking, alcohol drinking, BMI, fasting serum glucose, hypertension, and physical activity
		Total cholesterol	≥240 *vs.* <160 mg/dl (CC)	1.12 (1.00-1.25)	
		Total cholesterol	≥240 *vs.* <160 mg/dl (RC)	1.06 (0.94-1.19)	
		Women:			
		Total cholesterol	≥240 *vs.* <160 mg/dl (CC)	1.14 (0.96-1.35)	
		Total cholesterol	≥240 *vs.* <160 mg/dl (RC)	1.13 (0.94-1.36)	
Inoue et al [14], 2009, Japan, CS	312/27,724 (40-69y), 10.2y	Men:			Age, study area, smoking status, weekly ethanol intake, and total serum cholesterol
		Triglycerides	≥150 *vs.* <150 mg/dl (CC)	1.71 (1.11-2.62)	
		Triglycerides	≥150 *vs.* <150 mg/dl (RC)	0.54 (0.26-1.11)	
		HDL cholesterol	≥40 *vs.* <40 mg/dl (CC)	1.15 (0.65-2.03)	
		HDL cholesterol	≥40 *vs.* <40 mg/dl (RC)	0.41 (0.14-1.16)	
		Women:			
		Triglycerides	≥150 *vs.* <150 mg/dl (CC)	1.00 (0.63-1.60)	
		Triglycerides	≥150 *vs.* <150 mg/dl (RC)	0.52 (0.24-1.13)	
		HDL cholesterol	≥50 *vs.* <50 mg/dl (CC)	1.12 (0.74-1.71)	
		HDL cholesterol	≥50 *vs.* <50 mg/dl (RC)	1.14 (0.63-2.06)	

(Continued)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories		RR/HR (95%CI)	Matched/Adjusted potential factors
Iso et al [38]*, 2009, Japan, CS	320/33,368 (40-69y), 12.4y	Men:			Age, BMI, pack year of smoking, ethanol intake, hypertension, diabetes, hyperlipidemia medication use, total vegetable intake, coffee intake and public health center
		Total cholesterol	≥240 *vs.* <160 mg/dl (CRC)	1.10 (0.67-1.80)	
		Total cholesterol	≥240 *vs.* <160 mg/dl (CC)	1.21 (0.68-2.14)	
		Total cholesterol	≥240 *vs.* <160 mg/dl (RC)	0.90 (0.36-2.27)	
		Women:			
		Total cholesterol	≥240 *vs.* <160 mg/dl (CRC)	1.64 (0.89-3.05)	
		Total cholesterol	≥240 *vs.* <160 mg/dl (CC)	1.83 (0.85-3.93)	
		Total cholesterol	≥240 *vs.* <160 mg/dl (RC)	1.36 (0.49-3.79)	
Ahn et al [28], 2009, Finland, CS	507/29,093 (50-69y), 18y	Men:			Age, intervention, level of education, systolic blood pressure, BMI, physical activity, duration of smoking, number of cigarettes smoked per day, saturates fat intake, polyunsaturated fat intake, total calorie, alcohol consumption, and serum total and HDL cholesterol for each other
		Total cholesterol	>276.7 *vs.* <203.9 mg/dl (CRC)	0.86 (0.65-1.13)	
		HDL cholesterol	>55.3 *vs.* <36.2 mg/dl (CRC)	1.01 (0.76-1.35)	
Ahmed et al [20]*, 2006, USA, CS	194/14,109 (45-64y), 11.5y	All:			Age. gender, family history of colorectal cancer, physical activity, non-steroidal anti-inflammatory drug use, NSAID use, aspirin use, pack-years of cigarette use, and grams of alcohol per week. Also adjusted for hormone-replacement therapy in women
		Triglycerides	≥150 *vs.* <150 mg/dl (CRC)	1.08 (0.8-1.5)	
		HDL cholesterol	High *vs.* Low (CRC)	0.84 (0.63-1.12)	

(Continued)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors
Tsushima et al [21], 2005, USA, CS	504/7619 (45-65y), 31y	Men: Triglycerides Q4 *vs.* Q1 (CRC) Triglycerides Q4 *vs.* Q1 (CC) Triglycerides Q4 *vs.* Q1 (RC)	 1.01 (0.77-1.33) 0.92 (0.67-1.26) 1.28 (0.75-2.18)	Age, elapsed time since last caloric intake, elapsed time since 50-g glucose load, BMI, heart rate, cigarette smoking history, alcohol intake, and 24-hr intake of total calories
Saydah et al [22], 2003, USA, NC-CS	173/519 (≥18y), 12y	All: Triglycerides Q4 *vs.* Q1 (CRC)	 0.69 (0.41-1.16)	Age, sex, race, time since last meal, and date of blood draw
Schoen et al [23], 1999, USA, CS	102/5849 (≥65y), 6.4y	All: Triglycerides Q4 *vs.* Q1 (CRC) HDL cholesterol Q4 *vs.* Q1 (CRC) LDL cholesterol Q4 *vs.* Q1 (CRC)	 1.4 (0.8-2.5) 0.6 (0.3-1.2) 0.5 (0.3-0.9)	Age, sex, and physical activity
Tulinius et al [15]**, 1997, Iceland, CS	338/22,946 (mean, 50.4y), 27y	Men: Triglycerides T3 *vs.* T1 (CRC) Total cholesterol T3 *vs.* T1 (CRC) Women: Triglycerides T3 *vs.* T1 (CRC) Total cholesterol T3 *vs.* T1 (CRC)	 1.39 (1.13-1.71) 1.32 (1.07-1.62) 1.35 (1.06-1.72) 1.33 (1.05-1.70)	Age

(Continued)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories		RR/HR (95%CI)	Matched/Adjusted potential factors
Gaard et al [29], 1997, Norway, CS	338/62,173 (20-49y), 14y	Men:			Age and attained age, BMI, height, smoking status, and menopausal status
		HDL cholesterol	≥1.66 vs. ≤1.19 mmol/L (CC)	0.99 (0.58-1.68)	
		HDL cholesterol	≥1.66 vs. ≤1.19 mmol/L (RC)	0.87 (0.41-1.86)	
		LDL cholesterol	≥4.65 vs. ≤3.17 mmol/L (CC)	0.99 (0.56-1.74)	
		LDL cholesterol	≥4.65 vs. ≤3.17 mmol/L (RC)	1.17 (0.52-2.64)	
		Women:			
		HDL cholesterol	≥1.66 vs. ≤1.19 mmol/L (CC)	1.23 (0.61-2.45)	
		HDL cholesterol	≥1.66 vs. ≤1.19 mmol/L (RC)	0.73 (0.35-1.53)	
		LDL cholesterol	≥4.65 vs. ≤3.17 mmol/L (CC)	0.57 (0.32-1.02)	
		LDL cholesterol	≥4.65 vs. ≤3.17 mmol/L (RC)	1.97 (0.78-4.97)	
Chyou et al [34], 1996, USA, CS	453/7945 (45-65y), 28y	Men:			Age
		Total cholesterol	≥240 *vs.* <200 mg/dl (CC)	0.74 (0.56-0.97)	
		Total cholesterol	≥240 *vs.* <200 mg/dl (RC)	1.10 (0.68-1.79)	
Schatzkin et al [35]*, 1988, USA, CS	130/12,488 (25-74y), 10y	Men:			Age, education, BMI, smoking, alcohol, fat as a percentage of calories, dietary fiber, age at first birth (women), age at menarche (women), parity (women), and cholesterol
		Total cholesterol	≥246 *vs.* ≤189 mg/dl (CRC)	0.59 (0.27-1.27)	
		Women:			
		Total cholesterol	>252 *vs.* <186 mg/dl (CRC)	1.00 (0.33-3.00)	

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories		RR/HR (95%CI)	Matched/Adjusted potential factors
Tornberg et al [27], 1986, Sweden, CS	839/92,898 (≤75y), 16y	Men:			Age
		Total cholesterol	≥276 vs. ≤224 mg/dl (CC)	1.17 (0.81-1.68)	
		Total cholesterol	≥276 vs. ≤224 mg/dl (RC)	1.65 (1.05-2.57)	
		Women:			
		Total cholesterol	≥276 vs. ≤224 mg/dl (CC)	1.23 (0.84-1.81)	
		Total cholesterol	≥276 vs. ≤224 mg/dl (RC)	1.23 (0.64-2.34)	
Sidney et al [36], 1986, USA, NC-CS	245/1,470 (mean, 64.6y), 14y	All:			Age, sex, race, and multiphasic checkup at the same facility
		Total cholesterol	Q4 vs. Q1 (CRC)	1.2 (0.8 -1.8)	

BMI: body mass index; CC: colon cancer; C-CS: case-control study; CI: confidence interval; CRC: colorectal cancer; CS: cohort study; HDL: high density lipoprotein; HR: hazards ratio; LDL: low density lipoprotein; NC-CS: nested case-control study; N/A: not available; RC: rectal cancer; RR: relative risk.

* Recalculate the RR by the method proposed by Hamling et al.

** Recalculate the RR by the method proposed by Xu et al.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary Table S3. Study quality scores of prospective studies included in the meta-analysis

First author, publication year [reference]	Representativeness of the exposed cohort	Selection of the unexposed cohort	Ascertainment of exposure	Outcome of interest not present at start of study	Control for important factor or additional factor*	Assessment of outcome	Follow-up long enough for outcomes to occur**	Adequacy of follow-up of cohorts***	Total quality scores
Li [16], 2019	★	★	★	★	★	★	★	★	9
Katzke [17], 2017	★	★	★	★	★★	★	★	★	9
Chandler [11], 2016	★	★	★	★	★★	★	★	★	9
Muka [24], 2016	★	★	★	★	★★	★	★	★	9
Lu [12], 2015	★	★	★	★	★★	★	★	★	9
Agnoli [18], 2014	★	★	★	★	★★	★	★	★	9
Shin [25], 2014	★	★	★	★	★	★	★	—	8
Strohmaier [37], 2013	★	★	★	★	★★	★	★	★	9
Van Duijnhoven [19], 2011	★	★	★	★	★★	★	—	★	8
Borena [13], 2011	★	★	★	★	★★	★	★	★	9
Kitahara [26], 2011	★	★	—	★	★★	★	★	★	8
Inoue [14], 2009	★	★	★	★	★	★	★	★	8
Iso [38], 2009	★	★	★	★	★★	★	★	★	9
Ahn [28], 2009	★	★	★	★	★★	★	★	★	9
Ahmed [20], 2006	★	★	★	★	★	★	★	★	8
Tsushima [21], 2005	★	★	★	★	★★	★	★	★	9
Saydah [22], 2003	★	★	★	★	—	★	★	★	7
Schoen [23], 1999	★	★	★	★	—	★	—	★	6
Tulinius [15], 1997	★	★	—	★	—	★	★	—	5
Gaard [29], 1997	★	★	★	★	★★	★	★	★	9

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Chyou [34], 1996	☆	☆	☆	☆	—	☆	☆	☆	7
Schatzkin [35],1988	☆	☆	☆	☆	☆☆	☆	☆	☆	9
Tornberg [27], 1986	☆	☆	☆	☆	—	☆	☆	—	6
Sidney [36], 1986	☆	☆	☆	☆	☆	☆	☆	☆	8

* Studies that controlled for body mass index received one star, whereas studies that controlled for other important confounders such as cigarette smoking, alcohol drinking, received an additional star.

** The study with a follow-up time >10 y was assigned one star.

*** The study with a follow-up rate >75% was assigned one star.

Supplementary Table S4. Subgroup analysis of the correlation between total cholesterol concentrations and colorectal cancer risk

	No. of studies	Summary RR (95% CIs)	I^2 Value (%)	$P_h{}^*$	$P_h{}^{**}$
Overall					
Colorectal cancer	15	1.15 (1.08-1.22)	36.8	0.017	
Colon cancer	7	1.08 (0.98-1.19)	44.1	0.057	
Rectal cancer	7	1.15 (1.05-1.26)	19.4	0.259	
Subgroup analyses					
Study quality					0.679
Medium	3	1.18 (0.99-1.41)	54.7	0.031	
High	12	1.14 (1.06-1.21)	31.3	0.062	
Number of cases					0.805
< 338	7	1.32 (1.14-1.52)	0	0.532	
≥ 338	8	1.11 (1.04-1.20)	46.6	0.010	
Follow-up years					0.416
< 13	6	1.12 (1.05-1.19)	20.0	0.206	
≥ 13	9	1.22 (1.07-1.40)	51.2	0.012	
Geographic location					0.143
North America	4	0.96 (0.76-1.21)	33.5	0.185	
Europe	8	1.20 (1.06-1.36)	49.7	0.011	
Asia	3	1.14 (1.08-1.20)	0	0.717	
Gender					0.107
Male	9	1.10 (0.99-1.23)	49.2	0.016	
Female	8	1.22 (1.11-1.34)	0	0.962	
Adjustment for confounders					
Body mass index					0.553
Yes	10	1.13 (1.04-1.22)	32.5	0.064	
No	5	1.18 (1.06-1.31)	45.0	0.052	
Alcohol drinking					0.196
Yes	9	1.11 (1.01-1.23)	40.3	0.033	
No	6	1.18 (1.09-1.28)	28.2	0.147	
Cigarette smoking					0.553
Yes	10	1.13 (1.04-1.22)	32.5	0.064	
No	5	1.18 (1.06-1.31)	45.0	0.052	
Physical activity					0.304
Yes	7	1.10 (0.98-1.23)	57.0	0.008	
No	8	1.18 (1.10-1.27)	13.8	0.273	
Dietary factors					0.634
Yes	8	1.13 (0.94-1.37)	51.8	0.008	
No	7	1.15 (1.09-1.21)	19.2	0.220	
Two aforementioned confounders					0.553
Yes	10	1.13 (1.04-1.22)	32.5	0.064	
No	5	1.18 (1.06-1.31)	45.0	0.052	
Three aforementioned confounders					0.348
Yes	9	1.11 (1.01-1.23)	40.3	0.033	
No	6	1.18 (1.09-1.28)	28.2	0.147	

CI: confidence interval; N/A: not available; RR: relative risk;
*P value for heterogeneity within each subgroup.
**P value for heterogeneity between subgroups with meta-regression analysis.

Supplementary Table S5. Subgroup analysis of the correlation between high-density lipoprotein cholesterol concentrations and colorectal cancer risk

	No. of studies	Summary RR (95% CIs)	I^2 Value (%)	P_h*	P_h**
Overall					
Colorectal cancer	11	0.86 (0.77-0.97)	28.8	0.117	
Colon cancer	3	0.85 (0.55-1.30)	70.8	0.008	
Rectal cancer	3	0.89 (0.65-1.22)	0	0.409	
Subgroup analyses					
Study quality					0.351
Medium	1	0.60 (0.30-1.20)	N/A	N/A	
High	10	0.87 (0.77-0.98)	29.1	0.120	
Number of cases					0.770
< 338	6	0.88 (0.75-1.04)	9.3	0.357	
≥ 338	5	0.84 (0.70-1.01)	47.7	0.054	
Follow-up years					0.273
< 13	5	0.79 (0.62-1.01)	52.2	0.033	
≥ 13	6	0.93 (0.85-1.01)	0	0.763	
Geographic location					0.421
North America	3	0.75 (0.60-0.94)	0	0.447	
Europe	6	0.87 (0.73-1.02)	38.9	0.090	
Asia	2	0.96 (0.75-1.23)	9.6	0.351	
Gender					0.476
Male	4	0.98 (0.80-1.21)	0	0.543	
Female	4	0.88 (0.71-1.09)	0	0.478	
Adjustment for confounders					
Body mass index					0.701
Yes	7	0.84 (0.71-0.99)	42.1	0.061	
No	4	0.89 (0.74-1.07)	4.6	0.392	
Alcohol drinking					0.196
Yes	9	0.86 (0.74-0.98)	42.9	0.045	
No	2	0.88 (0.65-1.18)	0	0.645	
Cigarette smoking					0.351
Yes	10	0.87 (0.77-0.98)	29.1	0.120	
No	1	0.60 (0.30-1.20)	N/A	N/A	
Physical activity					0.249
Yes	8	0.80 (0.68-0.96)	53.0	0.024	
No	3	0.96 (0.80-1.16)	0	0.700	
Dietary factors					0.242
Yes	5	0.77 (0.58-1.02)	60.6	0.019	
No	5	0.92 (0.85-1.00)	0	0.747	
Two aforementioned confounders					0.351
Yes	10	0.87 (0.77-0.98)	29.1	0.120	
No	1	0.60 (0.30-1.20)	N/A	N/A	
Three aforementioned confounders					0.409
Yes	7	0.82 (0.69-0.97)	55.4	0.022	
No	4	0.93 (0.78-1.12)	0	0.619	

CI: confidence interval; N/A: not available; RR: relative risk;
*P value for heterogeneity within each subgroup.
**P value for heterogeneity between subgroups with meta-regression analysis.

Supplementary Table S6. Subgroup analysis of the correlation between low-density lipoprotein cholesterol concentrations and colorectal cancer risk

	No. of studies	Summary RR (95% CIs)	I^2 Value (%)	P_h*	P_h**
Overall					
Colorectal cancer	5	1.03 (0.75-1.41)	69.4	0.001	
Colon cancer	2	0.85 (0.62-1.15)	0	0.469	
Rectal cancer	2	0.87 (0.49-1.55)	59.6	0.084	
Subgroup analyses					
Study quality					N/A
Medium	1	0.50 (0.29-0.87)	N/A	N/A	
High	4	1.11 (0.81-1.53)	65.3	0.003	
Number of cases					N/A
< 338	3	1.26 (0.67-2.40)	83.6	0.000	
≥ 338	2	0.84 (0.64-1.11)	23.4	0.258	
Follow-up years					0.062
< 13	2	0.68 (0.52-0.89)	0	0.442	
≥ 13	3	1.28 (0.88-1.87)	63.3	0.012	
Geographic location					N/A
North America	2	0.77 (0.35-1.73)	82.6	0.017	
Europe	3	1.12 (0.77-1.63)	69.4	0.002	
Asia	0	N/A	N/A	N/A	
Gender					N/A
Male	2	1.17 (0.47-2.87)	85.3	0.001	
Female	3	1.33 (1.01-1.76)	0	0.566	
Adjustment for confounders					
Body mass index					N/A
Yes	4	1.11 (0.81-1.53)	65.3	0.003	
No	1	0.50 (0.29-0.87)	N/A	N/A	
Alcohol drinking					N/A
Yes	3	1.20 (0.78-1.87)	76.1	0.002	
No	2	0.84 (0.54-1.32)	56.2	0.058	
Cigarette smoking					N/A
Yes	4	1.11 (0.81-1.53)	65.3	0.003	
No	1	0.50 (0.29-0.87)	N/A	N/A	
Physical activity					N/A
Yes	4	1.05 (0.68-1.62)	78.9	0.000	
No	1	0.98 (0.61-1.58)	N/A	N/A	
Dietary factors					N/A
Yes	3	1.20 (0.78-1.87)	76.1	0.002	
No	2	0.84 (0.54-1.32)	56.2	0.058	
Two aforementioned confounders					N/A
Yes	4	1.11 (0.81-1.53)	65.3	0.003	
No	1	0.50 (0.29-0.87)	N/A	N/A	
Three aforementioned confounders					N/A
Yes	3	1.20 (0.78-1.87)	76.1	0.002	
No	2	0.84 (0.54-1.32)	56.2	0.058	

CI: confidence interval; N/A: not available; RR: relative risk;
*P value for heterogeneity within each subgroup.
**P value for heterogeneity between subgroups with meta-regression analysis.

Supplementary Figure 1 Forest plots on the association between low-density lipoprotein cholesterol concentrations and colorectal cancer risk